https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1524277/full
BackgroundBrigatinib is approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cance...
frontiersbrigatinibinhibitproliferationinduce
https://pubmed.ncbi.nlm.nih.gov/34371380/
Metastatic pheochromocytoma and paraganglioma (PPGL) are rare diseases with dismal prognosis and standard therapies are lacking. We herein report the first...
in asustainedresponsebrigatinibpatient
https://www.mdpi.com/2077-0383/11/11/2963
(1) Background: The relative efficacy and safety of brigatinib compared with other next-generation anaplastic lymphoma kinase (ALK) inhibitors remains unclear,...
first linecomparisonefficacysafetybrigatinib